Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations
Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here. Pharmacokinetics over 28 days were assessed in Wistar rats, New Zealand white rabbits, and Balb/C mice following intramuscular injection. Two lead formulations were assessed for the prevention of an HIV infection in NSG-cmah-/- humanised mice to ensure antiviral activities were as anticipated according to the pharmacokinetics. Cmax was reached by 12, 48, and 24 h in rats, rabbits, and mice, respectively. Plasma concentrations were below the limit of detection (2 ng/mL) by 21 days in rats and rabbits, and 28 days in mice. Mice treated with SSPN formulations demonstrated undetectable viral loads (700 copies/mL detection limit), and HIV RNA remained undetectable 28 days post-infection in plasma, spleen, lung, and liver. The in vivo data presented here demonstrate that the combined prodrug/SSPN approach can provide a dramatically extended pharmacokinetic half-life across multiple preclinical species. Species differences in renal clearance of FTC mean that longer exposures are likely to be achievable in humans than in preclinical models.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Pharmaceutics - 15(2023), 7 vom: 27. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Curley, Paul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Emtricitabine |
|---|
| Anmerkungen: |
Date Revised 01.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pharmaceutics15071835 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36013890X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36013890X | ||
| 003 | DE-627 | ||
| 005 | 20231226082356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics15071835 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM36013890X | ||
| 035 | |a (NLM)37514020 | ||
| 035 | |a (PII)1835 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Curley, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here. Pharmacokinetics over 28 days were assessed in Wistar rats, New Zealand white rabbits, and Balb/C mice following intramuscular injection. Two lead formulations were assessed for the prevention of an HIV infection in NSG-cmah-/- humanised mice to ensure antiviral activities were as anticipated according to the pharmacokinetics. Cmax was reached by 12, 48, and 24 h in rats, rabbits, and mice, respectively. Plasma concentrations were below the limit of detection (2 ng/mL) by 21 days in rats and rabbits, and 28 days in mice. Mice treated with SSPN formulations demonstrated undetectable viral loads (700 copies/mL detection limit), and HIV RNA remained undetectable 28 days post-infection in plasma, spleen, lung, and liver. The in vivo data presented here demonstrate that the combined prodrug/SSPN approach can provide a dramatically extended pharmacokinetic half-life across multiple preclinical species. Species differences in renal clearance of FTC mean that longer exposures are likely to be achievable in humans than in preclinical models | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a emtricitabine | |
| 650 | 4 | |a long-acting | |
| 650 | 4 | |a nano | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 700 | 1 | |a Hobson, James J |e verfasserin |4 aut | |
| 700 | 1 | |a Liptrott, Neill J |e verfasserin |4 aut | |
| 700 | 1 | |a Makarov, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Khouja, Amer |e verfasserin |4 aut | |
| 700 | 1 | |a Tatham, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a David, Christopher A W |e verfasserin |4 aut | |
| 700 | 1 | |a Box, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Neary, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Sharp, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Pertinez, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Meyers, David |e verfasserin |4 aut | |
| 700 | 1 | |a Flexner, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Freel Meyers, Caren L |e verfasserin |4 aut | |
| 700 | 1 | |a Poluektova, Larisa |e verfasserin |4 aut | |
| 700 | 1 | |a Rannard, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 15(2023), 7 vom: 27. Juni |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:7 |g day:27 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics15071835 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 7 |b 27 |c 06 | ||